Breathe Well Live Well
|
GSK drug halves attacks in hard-to-treat asthma
Business Recorder (blog) An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success. Britain's biggest … |
View full post on asthma – Google News
 Telegraph.co.uk |
Experimental Asthma Drug Halves Attacks
The Inquisitr The Telegraph reports the medicine is called mepolizumab and treats a rare form of the condition in which white blood cells called eosinophils cause lung airways to become inflamed. The new asthma drug is injected, and reduces the number of eosinophils … Glaxo's Experimental Drug Halves Asthma Attacks in Study Experimental Drug May Cut Severe Asthma Attacks: Study GSK drug halves attacks in hard-to-treat asthma |
View full post on asthma – Google News
 Telegraph.co.uk |
Glaxo's Experimental Drug Halves Asthma Attacks in Study
Businessweek Among 621 participants with severe asthma, after a year of treatment, the rate of attacks requiring oral corticosteroids, emergency room visits or hospitalizations was about half for those taking one of three monthly doses of the drug, called … Experimental Drug May Cut Severe Asthma Attacks: Study GSK drug halves attacks in hard-to-treat asthma Experimental drug halves attacks in hard-to-treat asthma |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental drug halves attacks in hard-to-treat asthma
Fox News The injectable antibody treatment mepolizumab is designed to help a small group of people with asthma in which white blood cells called eosinophils cause inflammation of lung airways. It reduces the number of eosinophils by inhibiting an immune system … GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma Experimental Drug May Cut Severe Asthma Attacks: Study |
View full post on asthma – Google News
|
GSK drug halves attacks in hard-to-treat asthma
Chicago Tribune LONDON (Reuters) – An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success … |
View full post on asthma – Google News
|
GSK drug halves attacks in hard-to-treat asthma
Reuters LONDON (Reuters) – An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success … GlaxoSmithKline Sees Promise in New Drug for Severe Asthma |
View full post on asthma – Google News